Home › Compound Library › Rosuvastatin (Crestor)

Rosuvastatin (Crestor)

Statinprescriptionoral · inferred

Most potent HMG-CoA reductase inhibitor (statin) available. Hydrophilic with hepatic selectivity, lower myopathy risk than lipophilic statins. 20% oral bioavailability; minimally metabolized by CYP2C9 (not CYP3A4), resulting in fewer drug interactions than atorvastatin or simvastatin. 10 mg rosuvastatin approximates 20 mg atorvastatin or 40 mg simvastatin for LDL reduction. Also has the most favorable HDL-raising effect among statins.

Projected serum levels — 10 mg, once daily

Rosuvastatin (Crestor)
Rosuvastatin (Crestor) modeled serum levels, 10 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Rosuvastatin (Crestor) modeled serum levels with a loading dose of 14.6 mg, then 10 mg once daily The first dose is larger so levels approach steady state faster. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 10 mg once daily (oral).

Loading schedule: 14.6 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 2.4 mg, trough ≈ 0.92 mg body load. Population-based estimate over 15 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Statin
Route modeled
Oral
Model confidence
inferred
Half-life
19 h
Common dose
10 mg
Suggested maximum
40 mg/day
Reference dose range
2.5–40 mg (single dose)
Suggested cadence
once daily
Validated against
20 mg oral — Cmax 0.011 mg/L at 5 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Rosuvastatin (Crestor) CYP induction

    Carbamazepine (Tegretol) inducer of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~0.40x

  • danger
    CBD (Cannabidiol) + Rosuvastatin (Crestor) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~3.33x

  • danger
    Fluconazole + Rosuvastatin (Crestor) CYP inhibition

    Fluconazole reversible_inhibitor of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~3.33x

  • danger
    Fluvoxamine (Luvox) + Rosuvastatin (Crestor) CYP inhibition

    Fluvoxamine (Luvox) reversible_inhibitor of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~3.33x

  • danger
    Metronidazole (Flagyl) + Rosuvastatin (Crestor) CYP inhibition

    Metronidazole (Flagyl) reversible_inhibitor of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~3.33x

  • danger
    Milk Thistle (Silymarin / Silybin) + Rosuvastatin (Crestor) CYP inhibition

    Milk Thistle (Silymarin / Silybin) reversible_inhibitor of CYP2C9 predicted to change Rosuvastatin (Crestor) AUC by ~3.33x

Serum checks 53 modeled interaction pairings for rosuvastatin (crestor) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER trial) Ridker PM et al. · New England Journal of Medicine, 2008 DOI

    Landmark RCT (17,802 patients) demonstrating rosuvastatin 20 mg reduced cardiovascular events by 44% in patients with elevated CRP but normal LDL, fundamentally changing statin prescribing criteria.

  2. Comparative efficacy of rosuvastatin versus atorvastatin: the STELLAR trial Jones PH et al. · American Journal of Cardiology, 2003 DOI

    Head-to-head RCT confirming rosuvastatin's superior potency: 10 mg rosuvastatin reduced LDL by 46% versus 37% for atorvastatin 10 mg, establishing dose-equivalency ratios across the statin class.

2 published studies referenced in the app, each with a plain-language summary.